nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—CYP1A2—Dacarbazine—pancreatic cancer	0.119	0.327	CbGbCtD
Phenylpropanolamine—CYP1A2—Tamoxifen—pancreatic cancer	0.0945	0.26	CbGbCtD
Phenylpropanolamine—CYP1A2—Erlotinib—pancreatic cancer	0.0803	0.221	CbGbCtD
Phenylpropanolamine—CYP1A2—Fluorouracil—pancreatic cancer	0.0696	0.192	CbGbCtD
Phenylpropanolamine—Liver injury—Tamoxifen—pancreatic cancer	0.00745	0.0341	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Tamoxifen—pancreatic cancer	0.00627	0.0287	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Erlotinib—pancreatic cancer	0.00621	0.0284	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Sunitinib—pancreatic cancer	0.00537	0.0246	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Fluorouracil—pancreatic cancer	0.00364	0.0166	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Docetaxel—pancreatic cancer	0.00306	0.014	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Docetaxel—pancreatic cancer	0.00306	0.014	CcSEcCtD
Phenylpropanolamine—Irritability—Fluorouracil—pancreatic cancer	0.00294	0.0134	CcSEcCtD
Phenylpropanolamine—Flushing—Tamoxifen—pancreatic cancer	0.00292	0.0134	CcSEcCtD
Phenylpropanolamine—Ataxia—Fluorouracil—pancreatic cancer	0.00289	0.0132	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Tamoxifen—pancreatic cancer	0.00281	0.0129	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Erlotinib—pancreatic cancer	0.00278	0.0127	CcSEcCtD
Phenylpropanolamine—Flushing—Sunitinib—pancreatic cancer	0.0025	0.0114	CcSEcCtD
Phenylpropanolamine—Liver injury—Epirubicin—pancreatic cancer	0.00245	0.0112	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Sunitinib—pancreatic cancer	0.00241	0.011	CcSEcCtD
Phenylpropanolamine—Anxiety—Tamoxifen—pancreatic cancer	0.00233	0.0106	CcSEcCtD
Phenylpropanolamine—Anxiety—Erlotinib—pancreatic cancer	0.0023	0.0105	CcSEcCtD
Phenylpropanolamine—Liver injury—Doxorubicin—pancreatic cancer	0.00227	0.0104	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Epirubicin—pancreatic cancer	0.0022	0.01	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Epirubicin—pancreatic cancer	0.0021	0.0096	CcSEcCtD
Phenylpropanolamine—Ataxia—Docetaxel—pancreatic cancer	0.00209	0.00954	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Epirubicin—pancreatic cancer	0.00206	0.00943	CcSEcCtD
Phenylpropanolamine—Flushing—Irinotecan—pancreatic cancer	0.00206	0.00943	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Doxorubicin—pancreatic cancer	0.00203	0.00928	CcSEcCtD
Phenylpropanolamine—Insomnia—Tamoxifen—pancreatic cancer	0.00202	0.00925	CcSEcCtD
Phenylpropanolamine—Insomnia—Erlotinib—pancreatic cancer	0.002	0.00915	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Tamoxifen—pancreatic cancer	0.00199	0.00912	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Irinotecan—pancreatic cancer	0.00198	0.00907	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Erlotinib—pancreatic cancer	0.00197	0.00902	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Doxorubicin—pancreatic cancer	0.00194	0.00888	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Gemcitabine—pancreatic cancer	0.00193	0.00884	CcSEcCtD
Phenylpropanolamine—Constipation—Tamoxifen—pancreatic cancer	0.00191	0.00875	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Doxorubicin—pancreatic cancer	0.00191	0.00873	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Fluorouracil—pancreatic cancer	0.0019	0.00869	CcSEcCtD
Phenylpropanolamine—Constipation—Erlotinib—pancreatic cancer	0.00189	0.00865	CcSEcCtD
Phenylpropanolamine—Vision blurred—Fluorouracil—pancreatic cancer	0.00175	0.00798	CcSEcCtD
Phenylpropanolamine—Insomnia—Sunitinib—pancreatic cancer	0.00173	0.00792	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Sunitinib—pancreatic cancer	0.00171	0.00781	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00165	0.00753	CcSEcCtD
Phenylpropanolamine—Constipation—Sunitinib—pancreatic cancer	0.00164	0.00749	CcSEcCtD
Phenylpropanolamine—Confusional state—Irinotecan—pancreatic cancer	0.00159	0.00728	CcSEcCtD
Phenylpropanolamine—Confusional state—Fluorouracil—pancreatic cancer	0.00152	0.00697	CcSEcCtD
Phenylpropanolamine—Dizziness—Tamoxifen—pancreatic cancer	0.00148	0.00676	CcSEcCtD
Phenylpropanolamine—Tachycardia—Fluorouracil—pancreatic cancer	0.00148	0.00674	CcSEcCtD
Phenylpropanolamine—Hypotension—Irinotecan—pancreatic cancer	0.00148	0.00674	CcSEcCtD
Phenylpropanolamine—Dizziness—Erlotinib—pancreatic cancer	0.00146	0.00669	CcSEcCtD
Phenylpropanolamine—Hypotension—Gemcitabine—pancreatic cancer	0.00144	0.00657	CcSEcCtD
Phenylpropanolamine—Insomnia—Irinotecan—pancreatic cancer	0.00143	0.00653	CcSEcCtD
Phenylpropanolamine—Flushing—Docetaxel—pancreatic cancer	0.00143	0.00652	CcSEcCtD
Phenylpropanolamine—Vomiting—Tamoxifen—pancreatic cancer	0.00142	0.0065	CcSEcCtD
Phenylpropanolamine—Hypotension—Fluorouracil—pancreatic cancer	0.00141	0.00646	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Sunitinib—pancreatic cancer	0.00141	0.00645	CcSEcCtD
Phenylpropanolamine—Rash—Tamoxifen—pancreatic cancer	0.00141	0.00645	CcSEcCtD
Phenylpropanolamine—Dermatitis—Tamoxifen—pancreatic cancer	0.00141	0.00644	CcSEcCtD
Phenylpropanolamine—Ataxia—Epirubicin—pancreatic cancer	0.00141	0.00644	CcSEcCtD
Phenylpropanolamine—Vomiting—Erlotinib—pancreatic cancer	0.00141	0.00643	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Irinotecan—pancreatic cancer	0.00141	0.00643	CcSEcCtD
Phenylpropanolamine—Somnolence—Irinotecan—pancreatic cancer	0.0014	0.00641	CcSEcCtD
Phenylpropanolamine—Rash—Erlotinib—pancreatic cancer	0.0014	0.00638	CcSEcCtD
Phenylpropanolamine—Dermatitis—Erlotinib—pancreatic cancer	0.00139	0.00637	CcSEcCtD
Phenylpropanolamine—Insomnia—Gemcitabine—pancreatic cancer	0.00139	0.00636	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Docetaxel—pancreatic cancer	0.00137	0.00627	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Gemcitabine—pancreatic cancer	0.00137	0.00627	CcSEcCtD
Phenylpropanolamine—Insomnia—Fluorouracil—pancreatic cancer	0.00137	0.00625	CcSEcCtD
Phenylpropanolamine—Somnolence—Gemcitabine—pancreatic cancer	0.00137	0.00625	CcSEcCtD
Phenylpropanolamine—Constipation—Irinotecan—pancreatic cancer	0.00135	0.00617	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Fluorouracil—pancreatic cancer	0.00135	0.00616	CcSEcCtD
Phenylpropanolamine—Somnolence—Fluorouracil—pancreatic cancer	0.00134	0.00614	CcSEcCtD
Phenylpropanolamine—Nausea—Tamoxifen—pancreatic cancer	0.00133	0.00607	CcSEcCtD
Phenylpropanolamine—Constipation—Gemcitabine—pancreatic cancer	0.00131	0.00601	CcSEcCtD
Phenylpropanolamine—Nausea—Erlotinib—pancreatic cancer	0.00131	0.00601	CcSEcCtD
Phenylpropanolamine—Ataxia—Doxorubicin—pancreatic cancer	0.0013	0.00596	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Irinotecan—pancreatic cancer	0.0013	0.00595	CcSEcCtD
Phenylpropanolamine—Dizziness—Sunitinib—pancreatic cancer	0.00127	0.00579	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00127	0.00579	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00125	0.00569	CcSEcCtD
Phenylpropanolamine—Vomiting—Sunitinib—pancreatic cancer	0.00122	0.00557	CcSEcCtD
Phenylpropanolamine—Rash—Sunitinib—pancreatic cancer	0.00121	0.00552	CcSEcCtD
Phenylpropanolamine—Dermatitis—Sunitinib—pancreatic cancer	0.00121	0.00552	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Irinotecan—pancreatic cancer	0.00116	0.00532	CcSEcCtD
Phenylpropanolamine—Drowsiness—Epirubicin—pancreatic cancer	0.00115	0.00527	CcSEcCtD
Phenylpropanolamine—Nausea—Sunitinib—pancreatic cancer	0.00114	0.0052	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00111	0.00509	CcSEcCtD
Phenylpropanolamine—Confusional state—Docetaxel—pancreatic cancer	0.0011	0.00503	CcSEcCtD
Phenylpropanolamine—Drowsiness—Doxorubicin—pancreatic cancer	0.00107	0.00488	CcSEcCtD
Phenylpropanolamine—Tachycardia—Docetaxel—pancreatic cancer	0.00107	0.00487	CcSEcCtD
Phenylpropanolamine—Dizziness—Irinotecan—pancreatic cancer	0.00104	0.00477	CcSEcCtD
Phenylpropanolamine—Hypotension—Docetaxel—pancreatic cancer	0.00102	0.00466	CcSEcCtD
Phenylpropanolamine—Vomiting—Irinotecan—pancreatic cancer	0.001	0.00459	CcSEcCtD
Phenylpropanolamine—Dizziness—Fluorouracil—pancreatic cancer	0.001	0.00457	CcSEcCtD
Phenylpropanolamine—Rash—Irinotecan—pancreatic cancer	0.000995	0.00455	CcSEcCtD
Phenylpropanolamine—Dermatitis—Irinotecan—pancreatic cancer	0.000994	0.00455	CcSEcCtD
Phenylpropanolamine—Insomnia—Docetaxel—pancreatic cancer	0.000987	0.00451	CcSEcCtD
Phenylpropanolamine—Vomiting—Gemcitabine—pancreatic cancer	0.000978	0.00447	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Docetaxel—pancreatic cancer	0.000973	0.00445	CcSEcCtD
Phenylpropanolamine—Somnolence—Docetaxel—pancreatic cancer	0.00097	0.00443	CcSEcCtD
Phenylpropanolamine—Rash—Gemcitabine—pancreatic cancer	0.00097	0.00443	CcSEcCtD
Phenylpropanolamine—Dermatitis—Gemcitabine—pancreatic cancer	0.000969	0.00443	CcSEcCtD
Phenylpropanolamine—Flushing—Epirubicin—pancreatic cancer	0.000961	0.00439	CcSEcCtD
Phenylpropanolamine—Vomiting—Fluorouracil—pancreatic cancer	0.000961	0.00439	CcSEcCtD
Phenylpropanolamine—Rash—Fluorouracil—pancreatic cancer	0.000953	0.00436	CcSEcCtD
Phenylpropanolamine—Dermatitis—Fluorouracil—pancreatic cancer	0.000952	0.00435	CcSEcCtD
Phenylpropanolamine—Nausea—Irinotecan—pancreatic cancer	0.000938	0.00429	CcSEcCtD
Phenylpropanolamine—Constipation—Docetaxel—pancreatic cancer	0.000933	0.00427	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Epirubicin—pancreatic cancer	0.000925	0.00423	CcSEcCtD
Phenylpropanolamine—Nausea—Gemcitabine—pancreatic cancer	0.000913	0.00417	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000899	0.00411	CcSEcCtD
Phenylpropanolamine—Nausea—Fluorouracil—pancreatic cancer	0.000898	0.0041	CcSEcCtD
Phenylpropanolamine—Flushing—Doxorubicin—pancreatic cancer	0.00089	0.00407	CcSEcCtD
Phenylpropanolamine—Tension—Epirubicin—pancreatic cancer	0.000885	0.00405	CcSEcCtD
Phenylpropanolamine—Nervousness—Epirubicin—pancreatic cancer	0.000876	0.004	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Doxorubicin—pancreatic cancer	0.000856	0.00391	CcSEcCtD
Phenylpropanolamine—Vision blurred—Epirubicin—pancreatic cancer	0.00085	0.00388	CcSEcCtD
Phenylpropanolamine—Agitation—Epirubicin—pancreatic cancer	0.000829	0.00379	CcSEcCtD
Phenylpropanolamine—Tension—Doxorubicin—pancreatic cancer	0.000819	0.00374	CcSEcCtD
Phenylpropanolamine—Nervousness—Doxorubicin—pancreatic cancer	0.00081	0.0037	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000804	0.00367	CcSEcCtD
Phenylpropanolamine—Vision blurred—Doxorubicin—pancreatic cancer	0.000786	0.00359	CcSEcCtD
Phenylpropanolamine—Agitation—Doxorubicin—pancreatic cancer	0.000767	0.00351	CcSEcCtD
Phenylpropanolamine—Anxiety—Epirubicin—pancreatic cancer	0.000765	0.0035	CcSEcCtD
Phenylpropanolamine—Confusional state—Epirubicin—pancreatic cancer	0.000742	0.00339	CcSEcCtD
Phenylpropanolamine—Dizziness—Docetaxel—pancreatic cancer	0.000722	0.0033	CcSEcCtD
Phenylpropanolamine—Tachycardia—Epirubicin—pancreatic cancer	0.000718	0.00328	CcSEcCtD
Phenylpropanolamine—Anxiety—Doxorubicin—pancreatic cancer	0.000708	0.00324	CcSEcCtD
Phenylpropanolamine—Vomiting—Docetaxel—pancreatic cancer	0.000694	0.00317	CcSEcCtD
Phenylpropanolamine—Rash—Docetaxel—pancreatic cancer	0.000688	0.00314	CcSEcCtD
Phenylpropanolamine—Hypotension—Epirubicin—pancreatic cancer	0.000688	0.00314	CcSEcCtD
Phenylpropanolamine—Dermatitis—Docetaxel—pancreatic cancer	0.000687	0.00314	CcSEcCtD
Phenylpropanolamine—Confusional state—Doxorubicin—pancreatic cancer	0.000687	0.00314	CcSEcCtD
Phenylpropanolamine—Insomnia—Epirubicin—pancreatic cancer	0.000666	0.00304	CcSEcCtD
Phenylpropanolamine—Tachycardia—Doxorubicin—pancreatic cancer	0.000665	0.00304	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Epirubicin—pancreatic cancer	0.000656	0.003	CcSEcCtD
Phenylpropanolamine—Somnolence—Epirubicin—pancreatic cancer	0.000654	0.00299	CcSEcCtD
Phenylpropanolamine—Nausea—Docetaxel—pancreatic cancer	0.000648	0.00296	CcSEcCtD
Phenylpropanolamine—Hypotension—Doxorubicin—pancreatic cancer	0.000636	0.00291	CcSEcCtD
Phenylpropanolamine—Constipation—Epirubicin—pancreatic cancer	0.000629	0.00288	CcSEcCtD
Phenylpropanolamine—Insomnia—Doxorubicin—pancreatic cancer	0.000616	0.00282	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000607	0.00278	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000607	0.00277	CcSEcCtD
Phenylpropanolamine—Somnolence—Doxorubicin—pancreatic cancer	0.000605	0.00277	CcSEcCtD
Phenylpropanolamine—Constipation—Doxorubicin—pancreatic cancer	0.000582	0.00266	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000561	0.00257	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000542	0.00248	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000502	0.00229	CcSEcCtD
Phenylpropanolamine—Dizziness—Epirubicin—pancreatic cancer	0.000487	0.00222	CcSEcCtD
Phenylpropanolamine—Vomiting—Epirubicin—pancreatic cancer	0.000468	0.00214	CcSEcCtD
Phenylpropanolamine—Rash—Epirubicin—pancreatic cancer	0.000464	0.00212	CcSEcCtD
Phenylpropanolamine—Dermatitis—Epirubicin—pancreatic cancer	0.000464	0.00212	CcSEcCtD
Phenylpropanolamine—Dizziness—Doxorubicin—pancreatic cancer	0.00045	0.00206	CcSEcCtD
Phenylpropanolamine—Nausea—Epirubicin—pancreatic cancer	0.000437	0.002	CcSEcCtD
Phenylpropanolamine—Vomiting—Doxorubicin—pancreatic cancer	0.000433	0.00198	CcSEcCtD
Phenylpropanolamine—Rash—Doxorubicin—pancreatic cancer	0.000429	0.00196	CcSEcCtD
Phenylpropanolamine—Dermatitis—Doxorubicin—pancreatic cancer	0.000429	0.00196	CcSEcCtD
Phenylpropanolamine—Nausea—Doxorubicin—pancreatic cancer	0.000405	0.00185	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GCG—pancreatic cancer	8.49e-05	0.000203	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HIF1A—pancreatic cancer	8.47e-05	0.000203	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TSC2—pancreatic cancer	8.45e-05	0.000202	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CXCL8—pancreatic cancer	8.36e-05	0.0002	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	8.28e-05	0.000198	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APOE—pancreatic cancer	8.27e-05	0.000198	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CD—pancreatic cancer	8.26e-05	0.000198	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TYMS—pancreatic cancer	8.21e-05	0.000196	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CXCL8—pancreatic cancer	8.18e-05	0.000196	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TGFB1—pancreatic cancer	8.16e-05	0.000195	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AGTR1—pancreatic cancer	8.1e-05	0.000194	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KDR—pancreatic cancer	8.1e-05	0.000194	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GLP1R—pancreatic cancer	8.09e-05	0.000193	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CD—pancreatic cancer	8.07e-05	0.000193	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STK11—pancreatic cancer	7.98e-05	0.000191	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TERT—pancreatic cancer	7.96e-05	0.00019	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—DPYD—pancreatic cancer	7.96e-05	0.00019	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CD—pancreatic cancer	7.93e-05	0.00019	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TERT—pancreatic cancer	7.79e-05	0.000186	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.75e-05	0.000185	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NFKBIA—pancreatic cancer	7.7e-05	0.000184	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NOTCH1—pancreatic cancer	7.63e-05	0.000182	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HIF1A—pancreatic cancer	7.61e-05	0.000182	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TSC2—pancreatic cancer	7.59e-05	0.000182	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—KRAS—pancreatic cancer	7.56e-05	0.000181	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	7.55e-05	0.000181	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SMAD4—pancreatic cancer	7.53e-05	0.00018	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CD—pancreatic cancer	7.5e-05	0.000179	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	7.47e-05	0.000179	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CG—pancreatic cancer	7.46e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—NRAS—pancreatic cancer	7.46e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CXCL8—pancreatic cancer	7.45e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HIF1A—pancreatic cancer	7.45e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOE—pancreatic cancer	7.43e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TSC2—pancreatic cancer	7.43e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EGF—pancreatic cancer	7.37e-05	0.000176	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HES1—pancreatic cancer	7.35e-05	0.000176	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KDR—pancreatic cancer	7.28e-05	0.000174	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOE—pancreatic cancer	7.27e-05	0.000174	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	7.21e-05	0.000173	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.2e-05	0.000172	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KDR—pancreatic cancer	7.12e-05	0.00017	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CB—pancreatic cancer	7.04e-05	0.000168	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SMAD4—pancreatic cancer	6.99e-05	0.000167	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PIK3CA—pancreatic cancer	6.95e-05	0.000166	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NFKBIA—pancreatic cancer	6.92e-05	0.000166	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CXCL8—pancreatic cancer	6.92e-05	0.000166	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CB—pancreatic cancer	6.91e-05	0.000165	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOTCH1—pancreatic cancer	6.86e-05	0.000164	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTGS2—pancreatic cancer	6.85e-05	0.000164	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HES1—pancreatic cancer	6.83e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—EGFR—pancreatic cancer	6.8e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NFKBIA—pancreatic cancer	6.77e-05	0.000162	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CXCL8—pancreatic cancer	6.76e-05	0.000162	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—pancreatic cancer	6.72e-05	0.000161	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOTCH1—pancreatic cancer	6.71e-05	0.00016	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CG—pancreatic cancer	6.71e-05	0.00016	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—NRAS—pancreatic cancer	6.71e-05	0.00016	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOE—pancreatic cancer	6.68e-05	0.00016	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EGF—pancreatic cancer	6.63e-05	0.000159	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	6.57e-05	0.000157	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CG—pancreatic cancer	6.56e-05	0.000157	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—NRAS—pancreatic cancer	6.56e-05	0.000157	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CD—pancreatic cancer	6.56e-05	0.000157	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CB—pancreatic cancer	6.54e-05	0.000156	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.5e-05	0.000155	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EGF—pancreatic cancer	6.48e-05	0.000155	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TERT—pancreatic cancer	6.44e-05	0.000154	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—HRAS—pancreatic cancer	6.43e-05	0.000154	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—KRAS—pancreatic cancer	6.42e-05	0.000154	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	6.28e-05	0.00015	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HIF1A—pancreatic cancer	6.16e-05	0.000147	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TSC2—pancreatic cancer	6.14e-05	0.000147	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—EGFR—pancreatic cancer	6.11e-05	0.000146	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	6.03e-05	0.000144	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOE—pancreatic cancer	6.01e-05	0.000144	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	5.98e-05	0.000143	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—EGFR—pancreatic cancer	5.98e-05	0.000143	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTEN—pancreatic cancer	5.98e-05	0.000143	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PIK3CA—pancreatic cancer	5.9e-05	0.000141	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CD—pancreatic cancer	5.9e-05	0.000141	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KDR—pancreatic cancer	5.89e-05	0.000141	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CD44—pancreatic cancer	5.85e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.84e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPARG—pancreatic cancer	5.82e-05	0.000139	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—KRAS—pancreatic cancer	5.77e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CD—pancreatic cancer	5.77e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.73e-05	0.000137	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	5.72e-05	0.000137	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CB—pancreatic cancer	5.72e-05	0.000137	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.71e-05	0.000137	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	5.71e-05	0.000137	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—pancreatic cancer	5.67e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.67e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—KRAS—pancreatic cancer	5.65e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GCG—pancreatic cancer	5.61e-05	0.000134	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	5.6e-05	0.000134	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	5.59e-05	0.000134	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	5.55e-05	0.000133	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CXCL8—pancreatic cancer	5.49e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	5.47e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HRAS—pancreatic cancer	5.46e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	5.43e-05	0.00013	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	5.43e-05	0.00013	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	5.36e-05	0.000128	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—pancreatic cancer	5.31e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PIK3CA—pancreatic cancer	5.3e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	5.3e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—STK11—pancreatic cancer	5.27e-05	0.000126	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—pancreatic cancer	5.26e-05	0.000126	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	5.21e-05	0.000124	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PIK3CA—pancreatic cancer	5.19e-05	0.000124	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	5.16e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CB—pancreatic cancer	5.14e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCND1—pancreatic cancer	5.12e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CTNNB1—pancreatic cancer	5.07e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	5.04e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	5.04e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CB—pancreatic cancer	5.03e-05	0.00012	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	4.98e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—pancreatic cancer	4.97e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.95e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	4.94e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTEN—pancreatic cancer	4.94e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CXCL8—pancreatic cancer	4.94e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HRAS—pancreatic cancer	4.91e-05	0.000117	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	4.83e-05	0.000116	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—pancreatic cancer	4.82e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	4.8e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	4.77e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	4.77e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	4.73e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.72e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	4.67e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	4.67e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	4.62e-05	0.000111	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	4.62e-05	0.00011	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	4.6e-05	0.00011	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	4.59e-05	0.00011	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SRC—pancreatic cancer	4.58e-05	0.00011	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—pancreatic cancer	4.58e-05	0.000109	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	4.56e-05	0.000109	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TYMS—pancreatic cancer	4.53e-05	0.000108	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	4.5e-05	0.000108	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	4.47e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—pancreatic cancer	4.46e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	4.46e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	4.44e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	4.43e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STAT3—pancreatic cancer	4.42e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NRAS—pancreatic cancer	4.41e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.39e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	4.37e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	4.34e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	4.34e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	4.33e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	4.29e-05	0.000103	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	4.24e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CA—pancreatic cancer	4.22e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	4.16e-05	9.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SRC—pancreatic cancer	4.12e-05	9.85e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—pancreatic cancer	4.1e-05	9.82e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	4.09e-05	9.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SRC—pancreatic cancer	4.03e-05	9.63e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EGFR—pancreatic cancer	4.01e-05	9.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	4.01e-05	9.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	4e-05	9.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTEN—pancreatic cancer	3.99e-05	9.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	3.99e-05	9.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	3.97e-05	9.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	3.97e-05	9.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	3.96e-05	9.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	3.92e-05	9.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	3.88e-05	9.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	3.88e-05	9.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	3.86e-05	9.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	3.86e-05	9.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	3.82e-05	9.15e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KRAS—pancreatic cancer	3.79e-05	9.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	3.72e-05	8.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	3.71e-05	8.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—pancreatic cancer	3.69e-05	8.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	3.69e-05	8.82e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOE—pancreatic cancer	3.69e-05	8.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	3.69e-05	8.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	3.68e-05	8.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	3.61e-05	8.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—pancreatic cancer	3.61e-05	8.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	3.61e-05	8.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	3.6e-05	8.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	3.59e-05	8.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	3.59e-05	8.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	3.55e-05	8.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	3.53e-05	8.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	3.5e-05	8.38e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.49e-05	8.35e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	3.48e-05	8.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	3.46e-05	8.27e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—pancreatic cancer	3.44e-05	8.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	3.42e-05	8.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	3.41e-05	8.15e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—pancreatic cancer	3.37e-05	8.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	3.36e-05	8.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	3.34e-05	7.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	3.34e-05	7.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	3.33e-05	7.97e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	3.33e-05	7.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	3.26e-05	7.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	3.24e-05	7.76e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HRAS—pancreatic cancer	3.22e-05	7.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	3.21e-05	7.68e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARG—pancreatic cancer	3.21e-05	7.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	3.21e-05	7.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	3.13e-05	7.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	3.1e-05	7.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	3.06e-05	7.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—pancreatic cancer	3.03e-05	7.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	3.02e-05	7.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	2.99e-05	7.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	2.99e-05	7.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	2.98e-05	7.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	2.98e-05	7.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—pancreatic cancer	2.96e-05	7.09e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	2.93e-05	7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	2.92e-05	6.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	2.9e-05	6.93e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—pancreatic cancer	2.85e-05	6.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	2.83e-05	6.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	2.82e-05	6.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	2.77e-05	6.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	2.77e-05	6.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	2.76e-05	6.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	2.71e-05	6.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	2.56e-05	6.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	2.56e-05	6.12e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.55e-05	6.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.53e-05	6.06e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.53e-05	6.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	2.5e-05	5.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	2.45e-05	5.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.35e-05	5.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	2.34e-05	5.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—pancreatic cancer	2.3e-05	5.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	2.28e-05	5.45e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.2e-05	5.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	2.18e-05	5.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	2.07e-05	4.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	1.92e-05	4.6e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.55e-05	3.72e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.27e-05	3.04e-05	CbGpPWpGaD
